Novo Nordisk A/S (NYSE:NVO) Shares Sold by Private Trust Co. NA

Private Trust Co. NA cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 4.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 28,598 shares of the company’s stock after selling 1,259 shares during the period. Private Trust Co. NA’s holdings in Novo Nordisk A/S were worth $2,460,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Rosenberg Matthew Hamilton boosted its stake in Novo Nordisk A/S by 2.5% in the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after acquiring an additional 94 shares during the period. Spinnaker Trust grew its stake in Novo Nordisk A/S by 1.1% during the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock worth $1,145,000 after buying an additional 100 shares during the last quarter. Marco Investment Management LLC increased its position in Novo Nordisk A/S by 1.5% in the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after buying an additional 100 shares during the period. Carr Financial Group Corp lifted its stake in Novo Nordisk A/S by 5.1% in the third quarter. Carr Financial Group Corp now owns 2,100 shares of the company’s stock valued at $250,000 after buying an additional 101 shares during the last quarter. Finally, Menard Financial Group LLC boosted its holdings in shares of Novo Nordisk A/S by 0.8% during the third quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock valued at $1,463,000 after acquiring an additional 102 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $89.25 on Friday. The company has a 50-day moving average of $84.71 and a two-hundred day moving average of $107.17. The stock has a market cap of $400.51 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.